Researchers analyzed data from 3,564 heart transplant recipients who also had type 2 diabetes. The study looked at the impact of using SGLT2 inhibitors, a class of medications often used to manage blood sugar and protect kidney function.
The findings showed that patients taking these medications had a significantly lower risk of all-cause mortality compared to those who did not. Additionally, the data suggested that kidney function remained stable or improved in these patients. Importantly, there was no increased risk of urinary tract infections (UTIs) for those using the medication.
Because this was an observational study, it shows a link between the medication and better outcomes rather than proving the medicine caused the change. While the results are encouraging for managing both heart health and diabetes, individual results can vary. Patients should talk to their doctors about how these findings might apply to their specific treatment plan.
Common questions
Can SGLT2 inhibitors help people with both a heart transplant and diabetes?
This study of 3,564 patients found that those taking SGLT2 inhibitors had a lower risk of all-cause mortality. The data also suggested these medications may help maintain or improve kidney function (eGFR) in patients who have both heart transplant history and type 2 diabetes.
Do SGLT2 inhibitors cause more urinary tract infections?
The study found no increased risk of urinary tract infections (UTI) for patients using SGLT2 inhibitors. The results showed an odds ratio of 0.77 with a p-value of 0.75, meaning the medication did not appear to increase infection rates in this group.
Is this study's evidence definitive for my treatment?
This was an observational study, which means it shows a link between SGLT2 inhibitors and lower mortality rather than proving direct cause. Because of these limitations, you should discuss your specific health needs and medications with your doctor.
